Chlorthalidone plus amiloride reduces the central systolic blood pressure in stage 1 hypertension patients

Detalhes bibliográficos
Autor(a) principal: Fernandes, Leticia Aparecida Barufi
Data de Publicação: 2016
Outros Autores: Cestario, Elizabeth do Espirito Santo, Cosenso-Martin, Luciana Neves, Martin, Jose Fernando Vilela, Yugar-Toledo, Juan Carlos, Fuchs, Flávio Danni
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRGS
Texto Completo: http://hdl.handle.net/10183/226317
Resumo: Background: Hypertension reduction strategies use blood pressure in the brachial artery as the primary endpoint. Individuals who achieve the target blood pressure reduction with antihypertensive treatment have residual cardiovascular risk attributed to the difference in pressure between the aorta and brachial artery. Antihypertensive treatment affects the intrinsic properties of the vascular wall and arterial stiffness markers and consequently the central pressure. Recent publications stress the importance of adequate control of the central compared to peripheral blood pressure. Related clinical implications suggest that individuals with normal peripheral but high central blood pressure should not receive antihypertensive drugs that act on the central pressure. Therefore, they are at greater cardiovascular risk. The aim of the study was to evaluate the effect of treatment with a thiazide diuretic versus losartan on the central blood pressure in stage 1 hypertensive patients. Methods: Twenty-five patients were randomized to the chlorthalidone 25 mg/amiloride 5 mg group (q.d.) and 25 patients received losartan 50 mg (b.i.d). The central systolic blood pressure (CSBP) and augmentation index (AIx 75) were assessed using applanation tonometry. The paired t-test was used to compare the systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), pulse pressure (PP), CSBP and AIx 75 between the thiazide and losartan groups at baseline and after 6 months of treatment. Results: Significant reductions in CSBP (123.3 ± 14.2 vs. 113.4 ± 111.4, P = 0.0103) and AIx 75 (87.7 ± 9.6 vs. 83.8 ± 8.9, P = 0.0289) were observed after 6 months of drug treatment with chlorthalidone 25 mg/amiloride 5 mg (q.d.). The administration of losartan 50 mg (b.i.d) did not reduce the CSBP and there were insignificant changes in the AIx 75. Conclusions: Six-month treatment of chlorthalidone/amiloride but not losartan reduces the CSBP and AIx 75 in adults with stage 1 hypertension.
id UFRGS-2_1319f8d8232c26cd7f9095ffaa98f418
oai_identifier_str oai:www.lume.ufrgs.br:10183/226317
network_acronym_str UFRGS-2
network_name_str Repositório Institucional da UFRGS
repository_id_str
spelling Fernandes, Leticia Aparecida BarufiCestario, Elizabeth do Espirito SantoCosenso-Martin, Luciana NevesMartin, Jose Fernando VilelaYugar-Toledo, Juan CarlosFuchs, Flávio Danni2021-08-31T04:21:03Z20161923-2829http://hdl.handle.net/10183/226317001130052Background: Hypertension reduction strategies use blood pressure in the brachial artery as the primary endpoint. Individuals who achieve the target blood pressure reduction with antihypertensive treatment have residual cardiovascular risk attributed to the difference in pressure between the aorta and brachial artery. Antihypertensive treatment affects the intrinsic properties of the vascular wall and arterial stiffness markers and consequently the central pressure. Recent publications stress the importance of adequate control of the central compared to peripheral blood pressure. Related clinical implications suggest that individuals with normal peripheral but high central blood pressure should not receive antihypertensive drugs that act on the central pressure. Therefore, they are at greater cardiovascular risk. The aim of the study was to evaluate the effect of treatment with a thiazide diuretic versus losartan on the central blood pressure in stage 1 hypertensive patients. Methods: Twenty-five patients were randomized to the chlorthalidone 25 mg/amiloride 5 mg group (q.d.) and 25 patients received losartan 50 mg (b.i.d). The central systolic blood pressure (CSBP) and augmentation index (AIx 75) were assessed using applanation tonometry. The paired t-test was used to compare the systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), pulse pressure (PP), CSBP and AIx 75 between the thiazide and losartan groups at baseline and after 6 months of treatment. Results: Significant reductions in CSBP (123.3 ± 14.2 vs. 113.4 ± 111.4, P = 0.0103) and AIx 75 (87.7 ± 9.6 vs. 83.8 ± 8.9, P = 0.0289) were observed after 6 months of drug treatment with chlorthalidone 25 mg/amiloride 5 mg (q.d.). The administration of losartan 50 mg (b.i.d) did not reduce the CSBP and there were insignificant changes in the AIx 75. Conclusions: Six-month treatment of chlorthalidone/amiloride but not losartan reduces the CSBP and AIx 75 in adults with stage 1 hypertension.application/pdfengCardiology research. Quebec. Vol. 7, no. 6 (2016), p. 196-201.Pressão sanguíneaHipertensãoClortalidonaAmiloridaLosartanStage 1 hypertensionCentral systolic blood pressureChlorthalidoneAmilorideLosartanChlorthalidone plus amiloride reduces the central systolic blood pressure in stage 1 hypertension patientsEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001130052.pdf.txt001130052.pdf.txtExtracted Texttext/plain28797http://www.lume.ufrgs.br/bitstream/10183/226317/2/001130052.pdf.txt7872c1ba55267492dd61562a8d85da06MD52ORIGINAL001130052.pdfTexto completo (inglês)application/pdf591911http://www.lume.ufrgs.br/bitstream/10183/226317/1/001130052.pdf2739cd22031fb83763502ca05cb03552MD5110183/2263172021-09-19 04:31:32.790758oai:www.lume.ufrgs.br:10183/226317Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2021-09-19T07:31:32Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv Chlorthalidone plus amiloride reduces the central systolic blood pressure in stage 1 hypertension patients
title Chlorthalidone plus amiloride reduces the central systolic blood pressure in stage 1 hypertension patients
spellingShingle Chlorthalidone plus amiloride reduces the central systolic blood pressure in stage 1 hypertension patients
Fernandes, Leticia Aparecida Barufi
Pressão sanguínea
Hipertensão
Clortalidona
Amilorida
Losartan
Stage 1 hypertension
Central systolic blood pressure
Chlorthalidone
Amiloride
Losartan
title_short Chlorthalidone plus amiloride reduces the central systolic blood pressure in stage 1 hypertension patients
title_full Chlorthalidone plus amiloride reduces the central systolic blood pressure in stage 1 hypertension patients
title_fullStr Chlorthalidone plus amiloride reduces the central systolic blood pressure in stage 1 hypertension patients
title_full_unstemmed Chlorthalidone plus amiloride reduces the central systolic blood pressure in stage 1 hypertension patients
title_sort Chlorthalidone plus amiloride reduces the central systolic blood pressure in stage 1 hypertension patients
author Fernandes, Leticia Aparecida Barufi
author_facet Fernandes, Leticia Aparecida Barufi
Cestario, Elizabeth do Espirito Santo
Cosenso-Martin, Luciana Neves
Martin, Jose Fernando Vilela
Yugar-Toledo, Juan Carlos
Fuchs, Flávio Danni
author_role author
author2 Cestario, Elizabeth do Espirito Santo
Cosenso-Martin, Luciana Neves
Martin, Jose Fernando Vilela
Yugar-Toledo, Juan Carlos
Fuchs, Flávio Danni
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Fernandes, Leticia Aparecida Barufi
Cestario, Elizabeth do Espirito Santo
Cosenso-Martin, Luciana Neves
Martin, Jose Fernando Vilela
Yugar-Toledo, Juan Carlos
Fuchs, Flávio Danni
dc.subject.por.fl_str_mv Pressão sanguínea
Hipertensão
Clortalidona
Amilorida
Losartan
topic Pressão sanguínea
Hipertensão
Clortalidona
Amilorida
Losartan
Stage 1 hypertension
Central systolic blood pressure
Chlorthalidone
Amiloride
Losartan
dc.subject.eng.fl_str_mv Stage 1 hypertension
Central systolic blood pressure
Chlorthalidone
Amiloride
Losartan
description Background: Hypertension reduction strategies use blood pressure in the brachial artery as the primary endpoint. Individuals who achieve the target blood pressure reduction with antihypertensive treatment have residual cardiovascular risk attributed to the difference in pressure between the aorta and brachial artery. Antihypertensive treatment affects the intrinsic properties of the vascular wall and arterial stiffness markers and consequently the central pressure. Recent publications stress the importance of adequate control of the central compared to peripheral blood pressure. Related clinical implications suggest that individuals with normal peripheral but high central blood pressure should not receive antihypertensive drugs that act on the central pressure. Therefore, they are at greater cardiovascular risk. The aim of the study was to evaluate the effect of treatment with a thiazide diuretic versus losartan on the central blood pressure in stage 1 hypertensive patients. Methods: Twenty-five patients were randomized to the chlorthalidone 25 mg/amiloride 5 mg group (q.d.) and 25 patients received losartan 50 mg (b.i.d). The central systolic blood pressure (CSBP) and augmentation index (AIx 75) were assessed using applanation tonometry. The paired t-test was used to compare the systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), pulse pressure (PP), CSBP and AIx 75 between the thiazide and losartan groups at baseline and after 6 months of treatment. Results: Significant reductions in CSBP (123.3 ± 14.2 vs. 113.4 ± 111.4, P = 0.0103) and AIx 75 (87.7 ± 9.6 vs. 83.8 ± 8.9, P = 0.0289) were observed after 6 months of drug treatment with chlorthalidone 25 mg/amiloride 5 mg (q.d.). The administration of losartan 50 mg (b.i.d) did not reduce the CSBP and there were insignificant changes in the AIx 75. Conclusions: Six-month treatment of chlorthalidone/amiloride but not losartan reduces the CSBP and AIx 75 in adults with stage 1 hypertension.
publishDate 2016
dc.date.issued.fl_str_mv 2016
dc.date.accessioned.fl_str_mv 2021-08-31T04:21:03Z
dc.type.driver.fl_str_mv Estrangeiro
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/226317
dc.identifier.issn.pt_BR.fl_str_mv 1923-2829
dc.identifier.nrb.pt_BR.fl_str_mv 001130052
identifier_str_mv 1923-2829
001130052
url http://hdl.handle.net/10183/226317
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv Cardiology research. Quebec. Vol. 7, no. 6 (2016), p. 196-201.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/226317/2/001130052.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/226317/1/001130052.pdf
bitstream.checksum.fl_str_mv 7872c1ba55267492dd61562a8d85da06
2739cd22031fb83763502ca05cb03552
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv
_version_ 1801225034375626752